Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 27;40(9):253.
doi: 10.1007/s12032-023-02123-5.

CD4 T cells in chronic myeloid leukemia present MHC class II-dependent and IFN-γ-dependent cytotoxic capacity

Yirong Jiang #  1 , Jingwei Yao #  2 , Zhuoxin Yao #  1 , Yueting Huang  2 , Zhangkun Li  1 , Ziying Fan  1 , Yong Zhou  2 , Guowei Li  3 , Zhifeng Li  4 , Bing Xu  5
Affiliations

CD4 T cells in chronic myeloid leukemia present MHC class II-dependent and IFN-γ-dependent cytotoxic capacity

Yirong Jiang et al. Med Oncol. .

Abstract

At present, many therapeutic schemes have been used to improve the prognosis of patients with chronic myeloid leukemia (CML), but response remains poor in a small group of patients. CD4 T cell-mediated cytotoxicity has been found in various autoimmune diseases. This study analyzed the characteristics of CD4 T cell mediated cytotoxicity in CML patients and healthy people. The cytotoxicity of CD4 T cells was tested in using two CML cell lines, including the MHC class II-deficient K562 cells and the MHC class II-expressing KU812 cells. CD4 T cell-mediated lysis was minimal in K562 cells but was much higher in KU812 cells. In CML patients, the level of CD4 T cell-mediated lysis was limited to a certain level. Interestingly, pre-treating KU812 cells with IFN-γ could significantly elevate the expression of MHC class II and elevate the level of CD4 T cell-mediated lysis. Overall, these data indicated CD4 T cells could become a potential candidate for cytotoxic elimination of CML cells.

Keywords: CD4 T cells; Chronic myeloid leukemia; IFN-γ; MHC class II.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Rowley JD, Letter. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature. 1973;243(5405):290–3. https://doi.org/10.1038/243290a0published . Online First: 1973/06/01]. - DOI - PubMed
    1. Hoglund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol. 2015;94(Suppl 2):241–7. : 10.1007/s00277-015-2314-2published Online First: 2015/03/31]. - DOI
    1. Quintas-Cardama A, Cortes JE. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc. 2006;81(7):973–88. : 10.4065/81.7.973published Online First: 2006/07/14]. - DOI - PubMed
    1. Siegel RL, Miller KD, Wagle NS, Jemal A, Cancer statistics. 2023. CA Cancer J Clin 2023;73(1):17–48 doi: 10.3322/caac.21763published Online First: 2023/01/13].
    1. Sasaki K, Strom SS, O’Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2(5):e186–93. https://doi.org/10.1016/S2352-3026(15 . )00048-4published Online First: 2015/12/22]. - DOI - PubMed - PMC

LinkOut - more resources